BIOVALENCE TECHNOLOGIES PTE. LTD.
Last Updated: 13 Apr 2026
Biovalence Technologies is a recombinant proteomics biotech dedicated to improving human and animal lives through innovative protein-based solutions. Our flagship product, RetroMAD1, is a novel, orally administrable chimeric protein with potent anti-viral properties, demonstrated to be effective in reducing clinical signs and mortality rates in animals infected with various viruses, including feline viruses and canine parvovirus. With a strong focus on pet healthcare, we are generating revenue and saving lives, while also exploring potential applications in human diseases such as Herpes, Dengue, AIDS, and Ebola. Our recent discovery of a mutation in SARS-CoV-2 similar to other viruses suggests promising opportunities for developing a treatment for COVID-19.
Country of registration | Singapore |
Registration number | 201723190D |
Local SIC | |
Incorporation date | 15 Aug 2017 |
Company age | 8 years 9 months |
Official entity type | Private Limited Company |
No. of officers | 17 |
Contact
Address:
7500A BEACH ROAD, #06-307, THE PLAZA, Singapore 199591
Access Key Decision Makers
This is the legal entity page of BIOVALENCE TECHNOLOGIES PTE. LTD.. To access company info, company size, news , key makers’ emails, visit the profile pages above.
Associated business (1)
- BIOVALENCE TECHNOLOGIES PTE LTDView MoreSingaporeBiovalence Technologies is a recombinant proteomics biotech dedicated to improving human and animal lives through innovative protein-based solutions. Our flagship product, RetroMAD1, is a novel, orally administrable chimeric protein with potent anti-viral properties, demonstrated to be effective in reducing clinical signs and mortality rates in animals infected with various viruses, including feline viruses and canine parvovirus. With a strong focus on pet healthcare, we are generating revenue and saving lives, while also exploring potential applications in human diseases such as Herpes, Dengue, AIDS, and Ebola. Our recent discovery of a mutation in SARS-CoV-2 similar to other viruses suggests promising opportunities for developing a treatment for COVID-19.
This is the legal entity page of BIOVALENCE TECHNOLOGIES PTE. LTD.. To access company info, company size, news, key maker's emails, visit the profile pages above.
Financials
Revenue | 1 - 10m |
Share Capital - Ordinary shares | SGD 5,167,594 |
Share Capital - Ordinary shares | USD 1,910,000 |
Last updated: 13 Apr 2026
* This information is provided to the best of our research ability and we make no warranties for any inaccuracies or omissions.
Discover More Companies
Lookalike companies
* This profile contains information from ACRA Information on Corporate Entities from Accounting and Corporate Regulatory Authority which is made available under the terms of the Singapore Open Data Licence version 1.0. Information and datasets on our website are provided on an “as is” and “as available” basis. This website makes no representations or warranties concerning the datasets, including but not limited to any representation or warranty as to the accuracy, completeness, reliability, continued availability, timeliness, non-infringement, title, quality, or fitness for any particular purpose of the datasets to the fullest extent permitted by the law.
Frequently Asked Questions (FAQ)
- What is the address of BIOVALENCE TECHNOLOGIES PTE. LTD.?
- Where is BIOVALENCE TECHNOLOGIES PTE. LTD.'s headquarter?
- What is BIOVALENCE TECHNOLOGIES PTE. LTD.'s contact number?
- What BIOVALENCE TECHNOLOGIES PTE. LTD.'s spending power?
- Does BIOVALENCE TECHNOLOGIES PTE. LTD. have a presence in the domain it operates in?